



PRIME
PHARMACEUTICALS



*Devoted to Discovery
Committed to Care*

About Prime



At Prime, we are dedicated to making a positive transformation in healthcare outcomes for people worldwide. Since our establishment in 1968, we have continually grown and remain committed to delivering products and services that surpass expectations in terms of quality and value.

Our Research and Development encompasses all stages of formulation development, resulting in a diverse portfolio of generics and specialty medicines. In alignment with our dedication to innovation, we have invested in three EMA-compliant manufacturing facilities.

The first facility specializes in biosimilar injectables, while the second facility is equipped for the production of oral tablets, capsules, liquids and semi-solids. The third facility is focused on producing of beta-lactam range of tablets, capsules, liquids and semi-solids. Supported by our capable regulatory team, we facilitate dossier filings for more than 50 regulated and semi-regulated markets.

Vision

Our vision is to be a leading global pharmaceutical company, renowned for bringing out research-driven molecules and serving our patient with best in class efficacious products and care. We aspire to set new standards through innovation, excellence, and rapid growth, becoming the trusted partner for healthcare professionals and patients worldwide.

Mission

Our mission is to lead the pharmaceutical industry as the fastest-growing, research-driven manufacturing and marketing company. By prioritizing the needs of patients and healthcare providers, we aim to enhance global health outcomes and improve quality of life. Through collaboration, excellence and a patient-centric approach, we endeavour to be a beacon of progress in the pharmaceutical landscape and setting new benchmarks for the industry.

Values



Passion :

We are driven by passion and dedication in everything we do, striving for excellence and continuously challenging ourselves to innovate and improve.



Responsibility :

We take responsibility for our actions, decisions and their impact on our stakeholders, communities and the environment, demonstrating accountability and ethical conduct at all times.



Integrity :

We uphold the highest standards of integrity, honesty, and transparency in our relationships, operations and communications, building trust and credibility with our customers, partners and employees.



Meaningful Innovation :

We embrace creativity and innovation to develop products, services and solutions that address real-world challenges and create meaningful value for our customers, contributing to positive change and advancement in society.



Empowerment :

We empower our employees to thrive, grow and succeed, fostering a culture of collaboration, respect, and inclusivity, where diversity is celebrated and every voice is heard and valued.

Our Journey



2024

- Completed clinical trials for two bio-similar products
- Initiated the filing process for products in the EU
- Triggered EMA audit for Beta-lactam & General OSD, semi solids and liquids
- Established offices in Switzerland, Malaysia and Nigeria

2022

- Established offices in Costa Rica, Spain, UAE and USA

2016

- Opened our first international office in Vietnam

1968

- Commenced business operations

2023

- Invested in EU-compliant general and beta-lactam facilities
- Took over management of two facilities in Algeria
- Initiated operations in Algeria
- Established a joint venture in Tanzania

2020

- Invested in EU compliant biosimilar facility
- Expanded global footprint to over 50 countries


2005

- Forayed into FDF exports

Global Presence



India Network



Global Network



Global Ventures

Algeria

- Established a joint venture for local manufacturing
- Strengthened our presence in North and Sub-Saharan African regions

Tanzania

- Started a joint venture for pharmaceutical business development, aiming to expand in East and Central African regions

Nigeria

- Ventured into a strategic partnership to market our products
- Enables full control over operations, promotion and brand building in Africa's largest market

Malaysia

- Initiated a joint venture for niche product promotion of prescription & OTC products
- Partnering with a leading local company to strengthen market presence

Business Verticals

- Research & Development
- Contract Research & Manufacturing Services
- Manufacturing
- Biosimilars
- Nutraceuticals & Supplements
- Finished Dosage Forms
- DC Granules & Premixes



Contract Research & Manufacturing Services



With an unwavering commitment to quality state of the art research, we are geared up to support and accelerate the product development and manufacturing programmes for our partner companies.

Formulation & Development

- Packaging Development
- Quality Assurance
- Technology Transfer
- Licensing In/Out
- Regulatory Services
- Target Identification
- NCE Research
- Drug Evaluation
- Drug Development
- Analytical Development

Our state-of-the-art R&D Facility is located in Mumbai, certified by the Department of Science & Industrial Research (DSIR), India



Dosage Formulations

- Modified Release Formulations
- Delayed Release Formulations
- ODT Based Formulations
- Injectable Formulations
- Multi-Unit Particulate Systems (MUPS) Formulations
- Oral Dissolving Formulations (ODF)
- Oral Liquids
- PFS, Vials, Cartridges

Therapeutic Focus

Our focus is on the development and commercialisation of human medicines in the following core therapeutic areas

- Oncology
- Cardiovascular
- Endocrinology
- Anti-infectives
- Ophthalmology
- Immunology
- Haematology




Manufacturing Capabilities



Biosimilar Facility

- State-of-the-art Greenfield facility situated in Chennai, India
- Designed & set up according to most stringent global standards
- Equipped for manufacturing vials, cartridges & pre-filled syringes
- A robust pipeline of complex bio-similar products
- Clinical trials are ongoing
- EU GMP is targeted for 2025



Chennai Biosimilar Plant

Ready Products

Drug Name - Strength

Insulin Glargine 100 IU/ ML	Human Insulin Regular 100 IU/ ML	Human Insulin - NPH 100 IU/ML	Liraglutide 6 MG/ML
Human Insulin Premix 30/70 100 IU/ ML	Enoxaparin Pre-Filled Syringe 20MG/40MG/60MG/80MG/100MG	Enoxaparin Cartridge 300 MG/ ML	



Ahmedabad Plant

Plant 1, India



- A state-of-the-art general oral facility located in Ahmedabad, India
- Oral Solids, Oral Liquids & Semi-solids (Creams,Gels & Ointments)
- Commissioned in February 2024
- WHO – GMP Accredited
- EU audit expected in Q4 2025

Plant 2, India

- A state-of-the-art Beta-lactam facility located in Ahmedabad, India
- Tablets, Capsules, Dry Syrups & Liquids
- WHO GMP, Kenya & Cambodia approved
- Prequalified by DIGEMID Peru and NAFDAC
- EU audit expected in Q4 2025

Annual Capacity

	Plant 1	Plant 2
Tablets	2 Bn	900 Mn
Capsules	720 Mn	300 Mn
Liquids & Syrups	27 Mn	24 Mn
Creams & Ointment	18 Mn	-




Manufacturing Capabilities



Plant 1, Algeria

- A state-of-the-art formulation facility for Beta-Lactam range of products
- Emphasising a strong presence in North and Sub-Saharan African regions



Algeria Plant 1



Algeria Plant 2

Plant 2, Algeria

- A state-of-the-art formulation manufacturing facility for general oral solids
- Designed as per global regulatory standards

Annual Capacity | Plant 1 | Plant 2

Tablets	150Mn	100 Mn
Sachets	50 Mn	70 Mn
Bottles	8 Mn	-

Nutraceuticals


- Unique Formulas
- Regulatory Compliances
- Constant Innovation
- Clinical Evidence
- Training & Support



Therapeutic Areas

- Women's Wellness
- Paediatric Health
- Chronic Lifestyle Management
- General Wellness





India | Algeria | Costa Rica | Malaysia | Nigeria | Spain | Switzerland | Tanzania | UAE | USA | Vietnam

+912249792500

info@primepharma.com

www.primepharma.com

Disclaimer: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes a patent infringement and liability for patent infringement is exclusively understood at buyer's risk.